Coeptis Therapeutics

Coeptis Therapeutics

Coeptis Therapeutics operates as a biopharmaceutical asset aggregator, publicly traded yet functioning more like a holding company for early-stage cell therapy programs. Its pipeline draws from two primary sources: CD38- and BCMA-targeted CAR-T assets licensed from the University of Pittsburgh, and an allogeneic NK cell platform acquired from Deverra Therapeutics. The firm's lead program, DVX-201, is an unmodified natural killer cell therapy developed at the Fred Hutchinson Cancer Center, originally tested in acute myeloid leukemia and myelodysplastic syndromes under a physician-sponsored IND. A second Pittsburgh-derived program targets CD38 in preclinical models of multiple myeloma. The geographic concentration is distinctly Pittsburgh-Seattle, reflecting the academic hubs where its in-licensed technologies were developed. The firm has confirmed no strategic pharma partnerships beyond these university and biotech licensor relationships. The clinical-stage pipeline remains preclinical or early Phase 1 across all disclosed programs. DVX-201 received FDA clearance for an IND in 2024, enabling Coeptis to transition the program from a physician-sponsored trial to a company-sponsored Phase 1 in relapsed/refractory AML. No efficacy data have been reported publicly yet. The Pittsburgh-licensed CAR-T constructs include a CD38-targeted candidate in preclinical evaluation and a BCMA program in early development. Coeptis does not operate any internal discovery engine; all pipeline candidates were in-licensed at the preclinical or early clinical stage. Cash runway and burn-rate specifics are not publicly broken out beyond SEC quarterly filings, but the firm operates as a Nasdaq-listed microcap (COEP) with a sub-$50 million market capitalization as of late 2024. Dave Mehalick leads the firm as CEO and President. The leadership bench and board composition are not heavily profiled in institutional media, though Mehalick's background includes roles at smaller publicly traded biotech and investment entities. Coeptis has no disclosed non-profit foundation or adjacent investment vehicle operating in parallel. Its corporate structure is a straightforward Delaware-incorporated holding company with wholly owned subsidiaries through which the clinical assets are held. No Tiger 21, YPO or external co-investment club affiliations have been publicly disclosed by management. Coeptis's structural distinction is that it operates as a publicly listed holding company for academic cell therapy programs, not as an operating biotech with internal discovery capabilities. This creates an unusual risk/reward profile — upside is tied entirely to clinical and regulatory success of licensed programs, with no manufacturing infrastructure to monetize in a downside scenario. The firm's pivot from a pre-IPO blank-check company to a clinical-stage cell therapy aggregator through the Deverra asset acquisition and Pitt licenses is its defining architecture, making it fundamentally a capital-access vehicle for university technology transfer offices rather than a traditional biopharma developer.